Revenue Growth Remains Modest but Steady
Total revenue grew 1.9% YoY to $2,477.8M in Q1 2026 from $2,431.0M in Q1 2025, indicating stable demand across Biogen's product portfolio despite competitive pressures in the neuroscience space.
BIOGEN INC. is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: Biogen delivered a solid Q1 2026 with revenue up 1.9% YoY to $2.48B, while net income surged 32.8% to $319.5M and operating cash flow nearly tripled to $645.5M, reflecting improved profitability and working capital management.
Drawn from management commentary in the Q1 2026 10-Q:
Total revenue grew 1.9% YoY to $2,477.8M in Q1 2026 from $2,431.0M in Q1 2025, indicating stable demand across Biogen's product portfolio despite competitive pressures in the neuroscience space.
Net income jumped to $319.5M from $240.5M a year ago, a 32.8% increase, suggesting meaningful operating leverage or reduced below-the-line costs such as lower interest expense or favorable tax items contributing to bottom-line expansion.
Operating cash flow surged 148.9% YoY to $645.5M from $259.3M, a dramatic improvement that likely reflects better working capital management, including changes in accounts receivable, payables, or deferred revenue, alongside higher net income.
Revenue
$2.48B
++1.93% YoY
EPS (Basic)
$2.17
++31.52% YoY
Add BIIB to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.